Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
Pfizer has officially thrown its hat in the weight-loss ring. The company’s GLP-1 receptor agonist, danuglipron, showed promise in an ongoing pharmacokinetic study, it announced Thursday. Pfizer plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback